Scientists Establish New Nonviral Method for CRISPR Using Gold … – Futurism
Futurism |
Scientists Establish New Nonviral Method for CRISPR Using Gold …
Futurism CRISPR’s method of delivery has been raised as one limitation of the otherwise revolutionary technology. Now, a team of scientists has successfully tested a … CRISPR-Gold fixes Duchenne muscular dystrophy mutation in mice …UC Berkeley Gold nanoparticle used to replace virus in new CRISPR approachPhys.Org CRISPR/Cas9 Disrupts Glaucoma Gene, Takes Pressure off Eyes in Disease ModelsGenetic Engineering & Biotechnology News (blog) New University all 6 news articles » |
UC Berkeley |
CRISPR-Gold fixes Duchenne muscular dystrophy mutation in mice
UC Berkeley Scientists at the University of California, Berkeley, have engineered a new way to deliver CRISPR-Cas9 gene-editing technology inside cells and have demonstrated in mice that the technology can repair the mutation that causes Duchenne muscular … Scientists Establish New Nonviral Method for CRISPR Using Gold NanoparticlesFuturism CRISPR/Cas9 Disrupts Glaucoma Gene, Takes Pressure off Eyes in Disease ModelsGenetic Engineering & Biotechnology News (blog) Gold nanoparticle used to replace virus in new CRISPR approachPhys.Org |
Boston Business Journal |
After bidding war, Cambridge gene therapy firm Dimension accepts $151M buyout
Boston Business Journal After weighing buyout offers from two out-of-state biotechs, Cambridge gene therapy firm Dimension Therapeutics said Tuesday that it has accepted the superior proposal — a $151 million deal that will allow the company to maintain a local presence. Shoving Regenxbio aside, Ultragenyx’s Emil Kakkis closes Dimension buyout deal with 400% premiumEndpoints News In RARE news, Dimension dumps Regenxbio for better offerBioPharma Dive Ultragenyx to Acquire Dimension TherapeuticsP&T Community |
|
UK’s Cell and Gene Therapy Catapult Partners with Japan
BioPharm International The Cell and Gene Therapy Catapult (CGT Catapult), a UK center of excellence for building up the cell and gene therapy sector in the UK, announced on Oct. 3, 2017 that it has signed a Memorandum of Understanding (MoU) with Japan’s Forum for Innovative … |